Production & Manufacturing

Norgine has confirmed a £23 million ($31 million) investment in its manufacturing facility in Hengoed, Wales, increasing the total capital directed toward the site to more than £50 million ($67 million) since 2022. The move is intended to strengthen...

Ensuring regulatory compliance in pharmaceutical Quality Control labs requires advanced analytical capabilities, robust data integrity systems, and strict adherence to evolving global GMP standards. By integrating lifecycle-based method validation, digital traceability, and ultra-trace impurity detection, QC laboratories safeguard product quality and patient safety at every stage of manufacturing.

Integrated health risk assessment in food and pharma sectors aligns toxicology, exposure modeling, and regulatory standards to address cumulative chemical risks across daily consumption and therapy. By harmonizing methodologies and leveraging shared data, regulators and manufacturers can build a more holistic, science-driven safety framework that protects long-term public health.

Advanced analytical technologies in pharma impurity testing are transforming how trace contaminants are detected, identified, and controlled across the drug lifecycle. With high-resolution instrumentation, automation, and AI-driven insights, the industry is strengthening precision, data integrity, and patient safety to meet increasingly stringent purity standards.

PFAS regulations in pharmaceutical supply chains are reshaping how critical materials are sourced, validated, and justified amid rising environmental scrutiny. Manufacturers must balance sustainability, regulatory compliance, and material performance to ensure uninterrupted delivery of safe and effective medicines.

Nitrosamine risk mitigation in global pharma manufacturing requires proactive control of chemical pathways, excipients, and operational practices to prevent trace-level carcinogenic impurities. Advanced analytics, rigorous risk assessments, and strengthened GMP frameworks are now essential to ensure long-term product safety and regulatory compliance.

As global pharmaceutical supply chains expand across diverse climates and sourcing regions, the risk of resilient fungal toxins entering drug products has intensified. Effective mycotoxins risk monitoring now demands proactive, data-driven oversight, advanced analytics, and integrated quality frameworks to protect patient safety at every stage of production.